Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 200 | 2024 | 21012 | 4.660 |
Why?
|
Mastectomy, Segmental | 60 | 2023 | 953 | 3.370 |
Why?
|
Radiotherapy, Adjuvant | 35 | 2024 | 1784 | 3.200 |
Why?
|
Mastectomy | 41 | 2024 | 1822 | 2.990 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 34 | 2021 | 926 | 1.760 |
Why?
|
Neoplasm Recurrence, Local | 94 | 2024 | 9277 | 1.750 |
Why?
|
Lymph Node Excision | 22 | 2023 | 1271 | 1.450 |
Why?
|
Carcinoma in Situ | 18 | 2016 | 791 | 1.360 |
Why?
|
Carcinoma, Ductal, Breast | 20 | 2016 | 1085 | 1.210 |
Why?
|
Lymph Nodes | 20 | 2024 | 3466 | 1.180 |
Why?
|
Radiation Injuries | 12 | 2017 | 1189 | 1.120 |
Why?
|
Mammaplasty | 10 | 2024 | 1239 | 1.070 |
Why?
|
Radiotherapy, Conformal | 9 | 2014 | 548 | 1.030 |
Why?
|
Combined Modality Therapy | 97 | 2019 | 8529 | 0.930 |
Why?
|
Axilla | 22 | 2023 | 624 | 0.790 |
Why?
|
Lymphatic Metastasis | 44 | 2024 | 2914 | 0.770 |
Why?
|
Lymphatic Irradiation | 5 | 2024 | 115 | 0.730 |
Why?
|
Brachytherapy | 8 | 2017 | 1223 | 0.680 |
Why?
|
Radiation Oncology | 9 | 2017 | 563 | 0.650 |
Why?
|
Radiotherapy | 18 | 2019 | 1499 | 0.630 |
Why?
|
Dermatomyositis | 1 | 2021 | 257 | 0.600 |
Why?
|
Neoplasm Staging | 55 | 2020 | 11106 | 0.590 |
Why?
|
Aromatase Inhibitors | 4 | 2022 | 513 | 0.560 |
Why?
|
Practice Guidelines as Topic | 6 | 2018 | 7389 | 0.540 |
Why?
|
Chemotherapy, Adjuvant | 28 | 2016 | 3514 | 0.530 |
Why?
|
Patient Satisfaction | 5 | 2015 | 3460 | 0.520 |
Why?
|
Female | 218 | 2024 | 392581 | 0.510 |
Why?
|
Sentinel Lymph Node Biopsy | 8 | 2023 | 732 | 0.490 |
Why?
|
Bone Neoplasms | 3 | 2023 | 2529 | 0.480 |
Why?
|
Tamoxifen | 14 | 2015 | 965 | 0.480 |
Why?
|
Fluorouracil | 10 | 2005 | 1639 | 0.480 |
Why?
|
Radiotherapy Dosage | 23 | 2020 | 2898 | 0.460 |
Why?
|
Mastectomy, Radical | 3 | 2003 | 19 | 0.450 |
Why?
|
Humans | 243 | 2024 | 761423 | 0.430 |
Why?
|
Antineoplastic Agents, Hormonal | 9 | 2019 | 1520 | 0.410 |
Why?
|
Breast | 10 | 2023 | 1966 | 0.370 |
Why?
|
Deglutition Disorders | 1 | 2017 | 625 | 0.370 |
Why?
|
Meta-Analysis as Topic | 6 | 2022 | 1377 | 0.370 |
Why?
|
SEER Program | 6 | 2013 | 1450 | 0.360 |
Why?
|
Cyclophosphamide | 9 | 2012 | 2218 | 0.360 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 27 | 2012 | 11740 | 0.350 |
Why?
|
Mastectomy, Modified Radical | 3 | 2000 | 62 | 0.350 |
Why?
|
Wound Healing | 1 | 2021 | 2803 | 0.350 |
Why?
|
Methotrexate | 7 | 2005 | 1718 | 0.320 |
Why?
|
Mastectomy, Simple | 2 | 2007 | 23 | 0.320 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 10203 | 0.280 |
Why?
|
Heart | 6 | 2018 | 4405 | 0.280 |
Why?
|
Seroma | 1 | 2007 | 75 | 0.280 |
Why?
|
Patient Compliance | 2 | 2020 | 2690 | 0.270 |
Why?
|
Middle Aged | 112 | 2024 | 220826 | 0.260 |
Why?
|
Radiosurgery | 3 | 2023 | 1342 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 10 | 2013 | 5302 | 0.250 |
Why?
|
Insurance, Liability | 2 | 2017 | 101 | 0.250 |
Why?
|
Aged | 94 | 2024 | 169235 | 0.250 |
Why?
|
Antineoplastic Agents | 10 | 2018 | 13637 | 0.240 |
Why?
|
Carcinoma, Lobular | 3 | 2005 | 481 | 0.240 |
Why?
|
Heart Diseases | 2 | 2017 | 2785 | 0.240 |
Why?
|
Nitriles | 1 | 2010 | 971 | 0.240 |
Why?
|
Lymphedema | 2 | 2023 | 525 | 0.240 |
Why?
|
Treatment Outcome | 44 | 2024 | 64651 | 0.230 |
Why?
|
Triazoles | 1 | 2010 | 903 | 0.230 |
Why?
|
Markov Chains | 4 | 2020 | 966 | 0.230 |
Why?
|
Lung Neoplasms | 14 | 2017 | 13337 | 0.230 |
Why?
|
Survival Rate | 22 | 2016 | 12720 | 0.230 |
Why?
|
Doxorubicin | 6 | 2012 | 2224 | 0.220 |
Why?
|
Neoplasm Invasiveness | 13 | 2018 | 3589 | 0.220 |
Why?
|
Particle Accelerators | 2 | 2003 | 174 | 0.210 |
Why?
|
Patient Selection | 6 | 2013 | 4244 | 0.210 |
Why?
|
Estrogen Antagonists | 1 | 2003 | 150 | 0.210 |
Why?
|
Survival Analysis | 22 | 2011 | 10089 | 0.210 |
Why?
|
Follow-Up Studies | 53 | 2016 | 39117 | 0.200 |
Why?
|
Disease-Free Survival | 14 | 2012 | 6814 | 0.200 |
Why?
|
Societies, Medical | 4 | 2016 | 3905 | 0.200 |
Why?
|
Age Factors | 17 | 2020 | 18400 | 0.190 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2017 | 1661 | 0.190 |
Why?
|
Malpractice | 2 | 2017 | 556 | 0.190 |
Why?
|
Postoperative Complications | 5 | 2019 | 15650 | 0.190 |
Why?
|
Pneumonectomy | 6 | 2013 | 1109 | 0.180 |
Why?
|
United States | 19 | 2021 | 72339 | 0.180 |
Why?
|
Medical Oncology | 3 | 2016 | 2321 | 0.180 |
Why?
|
Neoplasms, Second Primary | 7 | 2012 | 1051 | 0.170 |
Why?
|
Aged, 80 and over | 41 | 2021 | 58956 | 0.170 |
Why?
|
Adult | 88 | 2024 | 221148 | 0.170 |
Why?
|
Phyllodes Tumor | 1 | 2019 | 53 | 0.170 |
Why?
|
Prognosis | 36 | 2015 | 29620 | 0.170 |
Why?
|
Postoperative Care | 2 | 2003 | 1471 | 0.170 |
Why?
|
Mediastinum | 3 | 2017 | 267 | 0.160 |
Why?
|
Neoplasms, Multiple Primary | 6 | 2000 | 592 | 0.160 |
Why?
|
Treatment Failure | 11 | 2010 | 2642 | 0.160 |
Why?
|
Receptors, Estrogen | 8 | 2021 | 2208 | 0.160 |
Why?
|
Cost-Benefit Analysis | 6 | 2022 | 5492 | 0.160 |
Why?
|
Adenocarcinoma | 12 | 2012 | 6339 | 0.160 |
Why?
|
Ontario | 1 | 2019 | 398 | 0.160 |
Why?
|
Spinal Cord Compression | 1 | 2020 | 235 | 0.160 |
Why?
|
Pneumonia | 2 | 2009 | 2140 | 0.160 |
Why?
|
Prospective Studies | 23 | 2023 | 54415 | 0.150 |
Why?
|
United States Food and Drug Administration | 2 | 2017 | 1664 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 1998 | 646 | 0.150 |
Why?
|
Antidotes | 1 | 1998 | 137 | 0.150 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5335 | 0.150 |
Why?
|
Receptor, erbB-2 | 4 | 2023 | 2557 | 0.150 |
Why?
|
Age of Onset | 1 | 2004 | 3304 | 0.140 |
Why?
|
Rectal Neoplasms | 6 | 1998 | 1157 | 0.140 |
Why?
|
Retrospective Studies | 43 | 2019 | 80582 | 0.140 |
Why?
|
Medical Device Recalls | 1 | 2017 | 15 | 0.140 |
Why?
|
Decision Support Techniques | 4 | 2021 | 1998 | 0.140 |
Why?
|
Heartburn | 1 | 2017 | 68 | 0.140 |
Why?
|
Time Factors | 22 | 2017 | 39975 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2016 | 882 | 0.140 |
Why?
|
Leucovorin | 1 | 1998 | 642 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2011 | 422 | 0.130 |
Why?
|
Organs at Risk | 1 | 2018 | 359 | 0.130 |
Why?
|
Standard of Care | 1 | 2020 | 550 | 0.130 |
Why?
|
Lung | 3 | 2012 | 9995 | 0.130 |
Why?
|
Clinical Trials as Topic | 10 | 2019 | 8000 | 0.130 |
Why?
|
Equipment Safety | 1 | 2017 | 249 | 0.130 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 2110 | 0.130 |
Why?
|
Decision Making | 4 | 2021 | 3929 | 0.130 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2017 | 452 | 0.130 |
Why?
|
Electrons | 4 | 2006 | 265 | 0.120 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2001 | 549 | 0.120 |
Why?
|
Radiotherapy, High-Energy | 4 | 1992 | 228 | 0.120 |
Why?
|
Adenocarcinoma, Mucinous | 7 | 2006 | 517 | 0.120 |
Why?
|
Neoplasm Metastasis | 9 | 2009 | 4912 | 0.120 |
Why?
|
Rheumatic Diseases | 1 | 2001 | 648 | 0.120 |
Why?
|
Carcinoma | 3 | 1998 | 2330 | 0.120 |
Why?
|
China | 1 | 2020 | 2366 | 0.120 |
Why?
|
Equipment Failure Analysis | 1 | 2017 | 847 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2020 | 801 | 0.110 |
Why?
|
Microsurgery | 1 | 2019 | 795 | 0.110 |
Why?
|
Carcinoma, Large Cell | 2 | 2011 | 113 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3687 | 0.100 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 3418 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2328 | 0.100 |
Why?
|
Photons | 2 | 2014 | 589 | 0.100 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 531 | 0.100 |
Why?
|
Salvage Therapy | 7 | 2019 | 1264 | 0.100 |
Why?
|
Medical Errors | 2 | 2017 | 1260 | 0.100 |
Why?
|
Life Expectancy | 1 | 2018 | 1242 | 0.100 |
Why?
|
Incidence | 12 | 2019 | 21341 | 0.100 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2009 | 89 | 0.100 |
Why?
|
Pain | 2 | 2023 | 5071 | 0.090 |
Why?
|
Paget's Disease, Mammary | 2 | 2003 | 18 | 0.090 |
Why?
|
Palliative Care | 2 | 2023 | 3600 | 0.090 |
Why?
|
Actuarial Analysis | 8 | 1996 | 374 | 0.090 |
Why?
|
Posture | 2 | 2006 | 956 | 0.090 |
Why?
|
Risk Factors | 23 | 2018 | 74167 | 0.080 |
Why?
|
Databases, Factual | 4 | 2020 | 7956 | 0.080 |
Why?
|
Esthetics | 6 | 2006 | 330 | 0.080 |
Why?
|
Radiation Dosage | 3 | 2009 | 1958 | 0.080 |
Why?
|
Risk Assessment | 7 | 2016 | 23990 | 0.080 |
Why?
|
Fractures, Bone | 1 | 2020 | 2046 | 0.080 |
Why?
|
Tumor Burden | 4 | 2018 | 1890 | 0.080 |
Why?
|
Diabetes Complications | 2 | 2013 | 1315 | 0.080 |
Why?
|
Lymphoma | 2 | 2017 | 1901 | 0.070 |
Why?
|
Esophageal Neoplasms | 2 | 1995 | 1649 | 0.070 |
Why?
|
Lymphatic System | 1 | 1989 | 254 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2016 | 9418 | 0.070 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2011 | 339 | 0.070 |
Why?
|
Quality of Life | 2 | 2024 | 13361 | 0.070 |
Why?
|
Software | 2 | 2017 | 4434 | 0.060 |
Why?
|
Death Certificates | 1 | 2006 | 167 | 0.060 |
Why?
|
Barrett Esophagus | 1 | 2008 | 492 | 0.060 |
Why?
|
Sigmoid Neoplasms | 3 | 1989 | 54 | 0.060 |
Why?
|
Carcinoma, Medullary | 1 | 2004 | 115 | 0.060 |
Why?
|
Manuals as Topic | 1 | 2003 | 99 | 0.060 |
Why?
|
Proportional Hazards Models | 7 | 2015 | 12456 | 0.050 |
Why?
|
Drug Therapy | 1 | 2006 | 503 | 0.050 |
Why?
|
Multivariate Analysis | 8 | 2015 | 12058 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 1722 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2010 | 22168 | 0.050 |
Why?
|
Advisory Committees | 2 | 2006 | 786 | 0.050 |
Why?
|
Tattooing | 1 | 2003 | 57 | 0.050 |
Why?
|
Biopsy | 6 | 2009 | 6766 | 0.050 |
Why?
|
Linear Models | 3 | 2017 | 5869 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2000 | 1703 | 0.050 |
Why?
|
Male | 27 | 2021 | 360736 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 1994 | 1964 | 0.050 |
Why?
|
Mathematics | 1 | 2003 | 707 | 0.050 |
Why?
|
Arm | 3 | 1999 | 590 | 0.050 |
Why?
|
Surgical Flaps | 1 | 2010 | 1671 | 0.050 |
Why?
|
Scattering, Radiation | 1 | 2003 | 490 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6479 | 0.050 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2851 | 0.050 |
Why?
|
Mesothelioma | 3 | 1997 | 807 | 0.050 |
Why?
|
Telangiectasis | 2 | 2014 | 78 | 0.050 |
Why?
|
Dactinomycin | 1 | 2001 | 304 | 0.050 |
Why?
|
Breast Implants | 1 | 2024 | 411 | 0.040 |
Why?
|
Career Choice | 1 | 2007 | 756 | 0.040 |
Why?
|
Edema | 3 | 1999 | 767 | 0.040 |
Why?
|
Skin | 1 | 2014 | 4481 | 0.040 |
Why?
|
Laryngeal Neoplasms | 1 | 1984 | 514 | 0.040 |
Why?
|
Prevalence | 1 | 2017 | 15717 | 0.040 |
Why?
|
Teaching | 1 | 2007 | 1169 | 0.040 |
Why?
|
Logistic Models | 4 | 2017 | 13255 | 0.040 |
Why?
|
Preoperative Care | 2 | 1998 | 2242 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 869 | 0.040 |
Why?
|
Fluoroscopy | 1 | 2003 | 947 | 0.040 |
Why?
|
Genes, erbB-2 | 1 | 2019 | 162 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2015 | 11073 | 0.040 |
Why?
|
Neoadjuvant Therapy | 3 | 2012 | 2826 | 0.040 |
Why?
|
Faculty, Medical | 1 | 2007 | 1202 | 0.040 |
Why?
|
Rectum | 2 | 1997 | 892 | 0.040 |
Why?
|
Risk | 4 | 2019 | 9612 | 0.040 |
Why?
|
Relative Biological Effectiveness | 1 | 2019 | 312 | 0.040 |
Why?
|
Mammography | 5 | 2009 | 2430 | 0.040 |
Why?
|
Recurrence | 4 | 2010 | 8469 | 0.040 |
Why?
|
Product Recalls and Withdrawals | 1 | 2017 | 7 | 0.040 |
Why?
|
Technology, Radiologic | 1 | 2017 | 160 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2001 | 921 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 1998 | 479 | 0.030 |
Why?
|
Models, Economic | 1 | 2020 | 716 | 0.030 |
Why?
|
Mediastinal Neoplasms | 2 | 2010 | 401 | 0.030 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2016 | 190 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 4852 | 0.030 |
Why?
|
Device Approval | 1 | 2017 | 163 | 0.030 |
Why?
|
Equipment Design | 1 | 2003 | 3509 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2007 | 3667 | 0.030 |
Why?
|
Mass Screening | 2 | 2009 | 5428 | 0.030 |
Why?
|
Etanidazole | 1 | 1994 | 22 | 0.030 |
Why?
|
Cosmetics | 1 | 1996 | 102 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 2017 | 273 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2003 | 2525 | 0.030 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1994 | 39 | 0.030 |
Why?
|
Radiodermatitis | 1 | 2014 | 59 | 0.030 |
Why?
|
Fat Necrosis | 1 | 2014 | 60 | 0.030 |
Why?
|
Postmenopause | 1 | 2003 | 2513 | 0.030 |
Why?
|
Thiophenes | 1 | 1998 | 569 | 0.030 |
Why?
|
Forecasting | 2 | 2012 | 2928 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2478 | 0.030 |
Why?
|
Primary Ovarian Insufficiency | 1 | 1994 | 107 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 2013 | 283 | 0.030 |
Why?
|
Medicare | 2 | 2021 | 6770 | 0.030 |
Why?
|
Skin Pigmentation | 1 | 2014 | 277 | 0.020 |
Why?
|
Quinazolines | 1 | 1998 | 1371 | 0.020 |
Why?
|
Pleural Neoplasms | 1 | 1997 | 609 | 0.020 |
Why?
|
Colonic Neoplasms | 3 | 1988 | 2538 | 0.020 |
Why?
|
Colorectal Neoplasms | 2 | 2002 | 6935 | 0.020 |
Why?
|
Registries | 2 | 2006 | 8223 | 0.020 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 1008 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2016 | 751 | 0.020 |
Why?
|
Peritoneal Neoplasms | 2 | 1988 | 711 | 0.020 |
Why?
|
Comorbidity | 1 | 2005 | 10498 | 0.020 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 15 | 0.020 |
Why?
|
Feasibility Studies | 3 | 2014 | 5246 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 1992 | 449 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2281 | 0.020 |
Why?
|
Cricetinae | 1 | 1993 | 2425 | 0.020 |
Why?
|
Palpation | 1 | 2009 | 166 | 0.020 |
Why?
|
Vinblastine | 1 | 2010 | 488 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2319 | 0.020 |
Why?
|
Clavicle | 1 | 1991 | 224 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2009 | 4021 | 0.020 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2002 | 7825 | 0.020 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 1988 | 63 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 3023 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1994 | 710 | 0.020 |
Why?
|
Cisplatin | 2 | 2010 | 1650 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 3 | 2011 | 36423 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1998 | 3712 | 0.020 |
Why?
|
Sarcoma | 2 | 2002 | 1801 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5820 | 0.020 |
Why?
|
Colon, Sigmoid | 1 | 1988 | 124 | 0.020 |
Why?
|
Necrosis | 2 | 1992 | 1608 | 0.020 |
Why?
|
Europe | 2 | 1996 | 3423 | 0.020 |
Why?
|
Ultrasonography, Mammary | 1 | 2009 | 239 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1626 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 1129 | 0.020 |
Why?
|
Carboplatin | 1 | 2010 | 794 | 0.020 |
Why?
|
Phosphorus Radioisotopes | 1 | 1987 | 100 | 0.020 |
Why?
|
Radionuclide Imaging | 2 | 1988 | 1975 | 0.020 |
Why?
|
Cohort Studies | 6 | 2011 | 41446 | 0.020 |
Why?
|
Medicine | 1 | 2015 | 941 | 0.020 |
Why?
|
Esophagoscopy | 1 | 2008 | 396 | 0.020 |
Why?
|
Internship and Residency | 1 | 2007 | 5879 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1908 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2006 | 504 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1995 | 1666 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2003 | 20093 | 0.010 |
Why?
|
Craniopharyngioma | 1 | 1987 | 277 | 0.010 |
Why?
|
Specimen Handling | 1 | 2009 | 702 | 0.010 |
Why?
|
Career Mobility | 1 | 2007 | 259 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4014 | 0.010 |
Why?
|
Endometrial Neoplasms | 1 | 1994 | 1365 | 0.010 |
Why?
|
Epithelium | 1 | 2008 | 1603 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9330 | 0.010 |
Why?
|
Regression Analysis | 3 | 2000 | 6343 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 1994 | 2644 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 3 | 2003 | 20556 | 0.010 |
Why?
|
Methods | 2 | 1997 | 1074 | 0.010 |
Why?
|
Paclitaxel | 1 | 2010 | 1732 | 0.010 |
Why?
|
Esophagus | 1 | 2008 | 1031 | 0.010 |
Why?
|
Surgery, Plastic | 1 | 1989 | 643 | 0.010 |
Why?
|
Glottis | 1 | 1984 | 214 | 0.010 |
Why?
|
Blood Vessels | 1 | 1988 | 1113 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4572 | 0.010 |
Why?
|
Mentors | 1 | 2007 | 660 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2005 | 1626 | 0.010 |
Why?
|
Vocal Cords | 1 | 1984 | 522 | 0.010 |
Why?
|
Length of Stay | 1 | 2013 | 6422 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6238 | 0.010 |
Why?
|
Analysis of Variance | 2 | 2000 | 6231 | 0.010 |
Why?
|
International Cooperation | 1 | 2005 | 1422 | 0.010 |
Why?
|
Pituitary Neoplasms | 1 | 1987 | 1324 | 0.010 |
Why?
|
Thymidylate Synthase | 1 | 1998 | 74 | 0.010 |
Why?
|
Neoplasms | 2 | 2017 | 22164 | 0.010 |
Why?
|
HT29 Cells | 1 | 1998 | 193 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5819 | 0.010 |
Why?
|
Carcinoma, Lewis Lung | 1 | 1998 | 107 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1994 | 3613 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3201 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1998 | 11458 | 0.010 |
Why?
|
Health Care Costs | 1 | 2009 | 3243 | 0.010 |
Why?
|
Pilot Projects | 2 | 1999 | 8633 | 0.010 |
Why?
|
Abdominal Neoplasms | 1 | 1997 | 287 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1998 | 2016 | 0.010 |
Why?
|
Thoracic Neoplasms | 1 | 1997 | 267 | 0.010 |
Why?
|
Heart Failure | 1 | 1998 | 11674 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 26112 | 0.010 |
Why?
|
Drug Interactions | 1 | 1998 | 1414 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 12951 | 0.010 |
Why?
|
Young Adult | 2 | 2011 | 59207 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 8545 | 0.010 |
Why?
|
Ovarian Neoplasms | 2 | 2002 | 4876 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 5840 | 0.010 |
Why?
|
Ovariectomy | 1 | 1994 | 614 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2006 | 4946 | 0.010 |
Why?
|
Survivors | 1 | 2002 | 2371 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1998 | 6132 | 0.010 |
Why?
|
Rib Fractures | 1 | 1992 | 128 | 0.010 |
Why?
|
Pericarditis | 1 | 1992 | 134 | 0.010 |
Why?
|
Family Health | 1 | 1995 | 1257 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 1998 | 2386 | 0.010 |
Why?
|
Brachial Plexus | 1 | 1992 | 167 | 0.010 |
Why?
|
Vincristine | 1 | 1991 | 1036 | 0.000 |
Why?
|
Cell Survival | 1 | 1998 | 5790 | 0.000 |
Why?
|
Odds Ratio | 1 | 2000 | 9645 | 0.000 |
Why?
|
Neck | 1 | 1992 | 734 | 0.000 |
Why?
|
Dysgerminoma | 1 | 1986 | 66 | 0.000 |
Why?
|
Prednisone | 1 | 1991 | 1562 | 0.000 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1998 | 10766 | 0.000 |
Why?
|
Animals | 2 | 1998 | 168441 | 0.000 |
Why?
|
Injections, Intravenous | 1 | 1987 | 1380 | 0.000 |
Why?
|
Head and Neck Neoplasms | 1 | 1998 | 2892 | 0.000 |
Why?
|
Predictive Value of Tests | 2 | 1990 | 15262 | 0.000 |
Why?
|
Adolescent | 2 | 2009 | 88313 | 0.000 |
Why?
|
Melanoma | 1 | 2002 | 5709 | 0.000 |
Why?
|
Random Allocation | 1 | 1987 | 2394 | 0.000 |
Why?
|
Prostheses and Implants | 1 | 1989 | 1272 | 0.000 |
Why?
|
Hand | 1 | 1987 | 902 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1987 | 2358 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 22163 | 0.000 |
Why?
|
Testicular Neoplasms | 1 | 1986 | 799 | 0.000 |
Why?
|
Emergencies | 1 | 1986 | 1217 | 0.000 |
Why?
|
Physical Examination | 1 | 1985 | 1254 | 0.000 |
Why?
|
Disease Progression | 1 | 1995 | 13502 | 0.000 |
Why?
|
Reoperation | 1 | 1987 | 4303 | 0.000 |
Why?
|
Radiography | 1 | 1987 | 6966 | 0.000 |
Why?
|
Mice | 1 | 1998 | 81509 | 0.000 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1988 | 8999 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1986 | 12970 | 0.000 |
Why?
|
Child, Preschool | 1 | 1986 | 42254 | 0.000 |
Why?
|
Child | 1 | 1986 | 80162 | 0.000 |
Why?
|